Astrazeneca Share News (AZN)

AstraZeneca wins EU backing for heart drug, but suffers lung cancer setback

Dec 19 (Reuters) - AstraZeneca on Monday won European endorsement for its blockbuster drug, dapagliflozin, as a treatment for all forms of heart failure, the company said.

TOP NEWS: AstraZeneca receives host of EU approvals or recommendations

(Alliance News) - AstraZeneca PLC on Monday said it received a host of approvals or recommendations for approval for a handful of prospective treatments in the EU, but noted disappointing phase 3 trial results for Imfinzi.

LONDON MARKET OPEN: Stocks higher as China begins shaky reopening

(Alliance News) - Stock prices in London opened higher on Monday, but the FTSE 100 was lagging behind European counterparts, despite gains for oil and mining stocks.

AstraZeneca's Imfinzi plus Imjudo recommended for EU approval

(Sharecast News) - AstraZeneca said on Monday that its Imfinzi (durvalumab) and Imjudo (tremelimumab) combinations have been recommended for marketing authorisation in the European Union for advanced liver and lung cancers.

LONDON BRIEFING: Stocks called up, but prospect of Santa rally fades

(Alliance News) - The FTSE 100 index looked set to regain some lost ground early on Monday, having fallen to a four-week low last week.

AstraZeneca's Forziga recommended for EU use

(Sharecast News) - AstraZeneca's Forxiga drug has been recommended for approval in the EU for symptomatic chronic heart failure, the pharma company said on Monday.

European shares post worst weekly loss since September as recession fears mount

STOXX 600 drops 3.3% this week

*

HealthBeacon appoints new interim CFO, permanent CFO process ongoing

(Alliance News) - HealthBeacon PLC on Friday said it appointed a new interim chief financial officer, while the process to appoint a CFO on a permanent basis is ongoing.

C4X Holdings loss widens; outlook strong amid AstraZeneca partnership

(Alliance News) - C4X Discovery Holdings PLC on Thursday said its annual loss widened, but it remains positive in its outlook, citing a partner programme with AstraZeneca PLC.

LONDON BROKER RATINGS: Goldman Sachs likes Big Yellow, Great Portland

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

AstraZeneca and Merck receive US FDA extension for Lynparza review

(Alliance News) - AstraZeneca PLC on Thursday alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone.

FDA gives AstraZeneca extension on cancer drug application

(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.

LONDON BRIEFING: Lower open ahead of BoE, ECB; Currys swings to loss

(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions.

LONDON BROKER RATINGS: JPMorgan lowers opinion on UK housebuilders

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say

Dec 9 (Reuters) - The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.